Shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $42.4286.
CSTL has been the subject of several recent research reports. Canaccord Genuity Group cut their price target on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Weiss Ratings lowered Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Wall Street Zen downgraded Castle Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. KeyCorp set a $35.00 target price on Castle Biosciences in a report on Friday, May 29th. Finally, BTIG Research reduced their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th.
Get Our Latest Research Report on Castle Biosciences
Castle Biosciences Trading Down 1.6%
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) EPS for the quarter, hitting analysts’ consensus estimates of ($0.49). Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. The business had revenue of $84.23 million for the quarter, compared to analyst estimates of $79.23 million. As a group, sell-side analysts forecast that Castle Biosciences will post -1.56 EPS for the current year.
Insider Transactions at Castle Biosciences
In other Castle Biosciences news, insider Derek J. Maetzold sold 3,622 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $24.29, for a total value of $87,978.38. Following the transaction, the insider directly owned 12,368 shares of the company’s stock, valued at $300,418.72. This trade represents a 22.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,586 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $24.42, for a total transaction of $209,670.12. Following the sale, the chief operating officer directly owned 21,874 shares of the company’s stock, valued at approximately $534,163.08. This trade represents a 28.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 49,361 shares of company stock worth $1,119,278 over the last quarter. Corporate insiders own 6.10% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Federated Hermes Inc. acquired a new stake in shares of Castle Biosciences in the 4th quarter valued at approximately $26,000. Kemnay Advisory Services Inc. bought a new position in Castle Biosciences in the 4th quarter valued at approximately $35,000. Jones Financial Companies Lllp lifted its stake in Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after buying an additional 297 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Castle Biosciences by 63.7% in the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after buying an additional 976 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.
Castle Biosciences Company Profile
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Featured Articles
- Five stocks we like better than Castle Biosciences
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
